Literature DB >> 16386645

Natural killer and CD8 T cells dominate the response by human peripheral blood mononuclear cells to inactivated Francisella tularensis live vaccine strain.

Edmund J Gosselin1, Diane R Gosselin, Steven A Lotz.   

Abstract

Francisella tularensis is a category A biothreat agent, and as a result, it has recently generated much research interest. F. tularensis live vaccine strain (LVS) is an attenuated form of the virulent F. tularensis organism and has previously been used as a vaccine. However, because of safety concerns, it is no longer approved for this purpose. Thus, the use of inactivated organisms is preferable for vaccine purposes. Although many studies have been performed that examine human peripheral blood mononuclear cells (PBMC), and in particular CD4 T cells, responses to inactivated F. tularensis, there has been no study identifying the individual human cell populations within a mixed PBMC population that respond to this organism. We sought to address this deficit. Our results indicate that natural killer and CD8 T cells comprise the majority of cells responding to F. tularensis LVS. In addition, data suggest CD8 T cell responses are maximal when antibiotic-treated organisms are used and are minimal when formaldehyde-fixed organisms are used. Given the belief that CD8 T cells can play an important role in protection against F. tularensis infection, these studies have direct relevance to the development of F. tularensis vaccines that use inactivated organisms. In addition, important new knowledge is added to our understanding of the human immune response to F. tularensis LVS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16386645     DOI: 10.1016/j.humimm.2005.08.240

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  8 in total

1.  Coactivating signals for the hepatic lymphocyte gamma interferon response to Francisella tularensis.

Authors:  Jason R Wickstrum; Kee-Jong Hong; Sirosh Bokhari; Natalie Reed; Nicholas McWilliams; Rebecca T Horvat; Michael J Parmely
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

2.  Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).

Authors:  Susan M Twine; Mireille D Petit; Kelly M Fulton; Robert V House; J Wayne Conlan
Journal:  PLoS One       Date:  2010-04-02       Impact factor: 3.240

Review 3.  Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.

Authors:  Girish S Kirimanjeswara; Sofia Olmos; Chandra S Bakshi; Dennis W Metzger
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

4.  Downmodulation of vaccine-induced immunity and protection against the intracellular bacterium Francisella tularensis by the inhibitory receptor FcγRIIB.

Authors:  Brian J Franz; Ying Li; Constantine Bitsaktsis; Bibiana V Iglesias; Giang Pham; Raju Sunagar; Sudeep Kumar; Edmund J Gosselin
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

5.  Early infection-induced natural antibody response.

Authors:  Klara Kubelkova; Tomas Hudcovic; Hana Kozakova; Jaroslav Pejchal; Ales Macela
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

6.  Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model.

Authors:  Aimee L Signarovitz; Heather J Ray; Jieh-Juen Yu; M N Guentzel; James P Chambers; Karl E Klose; Bernard P Arulanandam
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

7.  Francisella tularensis subsp. tularensis induces a unique pulmonary inflammatory response: role of bacterial gene expression in temporal regulation of host defense responses.

Authors:  Kathie-Anne Walters; Rachael Olsufka; Rolf E Kuestner; Ji Hoon Cho; Hong Li; Gregory A Zornetzer; Kai Wang; Shawn J Skerrett; Adrian Ozinsky
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

8.  Tularemia vaccine development: paralysis or progress?

Authors:  Raju Sunagar; Sudeep Kumar; Brian J Franz; Edmund J Gosselin
Journal:  Vaccine (Auckl)       Date:  2016-05-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.